BRPI0411665A - uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina - Google Patents
uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotoninaInfo
- Publication number
- BRPI0411665A BRPI0411665A BRPI0411665-8A BRPI0411665A BRPI0411665A BR PI0411665 A BRPI0411665 A BR PI0411665A BR PI0411665 A BRPI0411665 A BR PI0411665A BR PI0411665 A BRPI0411665 A BR PI0411665A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- serotonin reuptake
- agomelatine
- kit
- pharmaceutically acceptable
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 title abstract 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 title abstract 3
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002629 agomelatine Drugs 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title 1
- 230000000697 serotonin reuptake Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 2
- 229940076279 serotonin Drugs 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"USO DE AGOMELATINA OU DE UM SEU SAL FARMACEUTICAMENTE ACEITáVEL, COMPOSIçãO FARMACêUTICA OU KIT, E, MéTODOS PARA O TRATAMENTO DE DOENçAS OU DISTúRBIOS RESPONSIVOS A UM INIBIDOR DA RECAPTAçãO DE SEROTONINA E PARA AUMENTAR E/OU PROPORCIONAR INìCIO MAIS RáPIDO DO EFEITO TERAPêUTICO DE UM INIBIDOR DA RECAPTAçãO DE SEROTONINA". A presente invenção refere-se ao uso de uma combinação de agomelatina e um inibidor da recaptação de serotonina (SRI), ou qualquer outro composto, que causa uma elevação no nível de serotonina extracelular, para o tratamento de depressão e de outros distúrbios afetivos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301031 | 2003-07-04 | ||
US48547903P | 2003-07-07 | 2003-07-07 | |
PCT/DK2004/000464 WO2005002562A1 (en) | 2003-07-04 | 2004-06-29 | The combination of a serotonin reuptake inhibitors and agomelatine |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0411665A true BRPI0411665A (pt) | 2006-08-08 |
Family
ID=33566216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411665-8A BRPI0411665A (pt) | 2003-07-04 | 2004-06-29 | uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina |
Country Status (17)
Country | Link |
---|---|
US (3) | US20060205754A1 (pt) |
EP (1) | EP1643985B1 (pt) |
JP (1) | JP2007513052A (pt) |
KR (1) | KR20060032598A (pt) |
CN (1) | CN1852706A (pt) |
AR (1) | AR047553A1 (pt) |
AT (1) | ATE499096T1 (pt) |
AU (1) | AU2004253225A1 (pt) |
BR (1) | BRPI0411665A (pt) |
CA (1) | CA2530880A1 (pt) |
DE (1) | DE602004031527D1 (pt) |
DK (1) | DK1643985T3 (pt) |
IL (1) | IL172965A0 (pt) |
IS (1) | IS8154A (pt) |
MX (1) | MXPA06000018A (pt) |
NO (1) | NO20060242L (pt) |
WO (1) | WO2005002562A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2884714B1 (fr) * | 2005-04-20 | 2011-05-06 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires |
FR2890563B1 (fr) * | 2005-09-09 | 2007-10-19 | Servier Lab | Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent |
FR2890564B1 (fr) * | 2005-09-09 | 2007-10-19 | Servier Lab | Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent |
FR2899472B1 (fr) * | 2006-04-07 | 2008-09-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee |
WO2008035177A2 (en) * | 2006-09-18 | 2008-03-27 | Copharm | Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor |
US7608737B2 (en) | 2007-05-01 | 2009-10-27 | Concert Pharmaceuticasl Inc. | Naphthyl(ethyl)acetamides |
US20080280991A1 (en) * | 2007-05-08 | 2008-11-13 | Auspex Pharmaceuticals, Inc. | Substituted naphthalenes |
FR2956031B1 (fr) * | 2010-02-11 | 2012-03-02 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc) |
EP2629615B1 (en) | 2010-10-22 | 2018-10-10 | Duke University | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies |
PL2517700T3 (pl) * | 2011-04-28 | 2013-12-31 | Zentiva Ks | Farmaceutyczne dopuszczalne kokryształy n-[2-(7-metoksy-1-naftylo]acetamidu i sposoby ich wytwarzania |
PH12012000132A1 (en) * | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
WO2013013060A1 (en) * | 2011-07-19 | 2013-01-24 | Lycus, Llc | Agomelatine derivatives |
EP2551257A1 (en) * | 2011-07-28 | 2013-01-30 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of agomelatine with co-crystal-formers |
WO2014024896A1 (ja) * | 2012-08-08 | 2014-02-13 | 株式会社メドレックス | アゴメラチンを含有する貼付剤組成物 |
WO2023154794A1 (en) * | 2022-02-09 | 2023-08-17 | University Of North Texas Health Science Center | Drug repurposing for delayed treatment of ischemic stroke |
CN116570579A (zh) * | 2023-06-13 | 2023-08-11 | 深圳市泛谷药业股份有限公司 | 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5470846A (en) * | 1994-01-14 | 1995-11-28 | Sandyk; Reuven | Treatment of neurological and mental disorders |
CA2134038C (en) | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
CA2194984C (en) | 1994-07-26 | 2002-07-02 | John Eugene Macor | 4-indole derivatives as serotonin agonists and antagonists |
US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
FR2744449B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
GB2336534A (en) * | 1998-04-24 | 1999-10-27 | Alec James Coppen | Anti-depressant - Folic Acid Combination |
UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
CA2445843A1 (en) * | 2001-05-01 | 2002-11-07 | H. Lundbeck A/S | The use of enantiomeric pure escitalopram |
US6617891B2 (en) * | 2001-09-26 | 2003-09-09 | Intel Corporation | Slew rate at buffers by isolating predriver from driver |
FR2834890B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible d'agomelatine |
-
2004
- 2004-06-28 AR ARP040102269A patent/AR047553A1/es unknown
- 2004-06-29 KR KR1020057024442A patent/KR20060032598A/ko not_active Application Discontinuation
- 2004-06-29 WO PCT/DK2004/000464 patent/WO2005002562A1/en active Application Filing
- 2004-06-29 BR BRPI0411665-8A patent/BRPI0411665A/pt not_active Application Discontinuation
- 2004-06-29 JP JP2006517965A patent/JP2007513052A/ja active Pending
- 2004-06-29 US US10/558,494 patent/US20060205754A1/en not_active Abandoned
- 2004-06-29 AT AT04738961T patent/ATE499096T1/de not_active IP Right Cessation
- 2004-06-29 EP EP04738961A patent/EP1643985B1/en not_active Expired - Lifetime
- 2004-06-29 MX MXPA06000018A patent/MXPA06000018A/es not_active Application Discontinuation
- 2004-06-29 CN CNA2004800191380A patent/CN1852706A/zh active Pending
- 2004-06-29 DE DE602004031527T patent/DE602004031527D1/de not_active Expired - Lifetime
- 2004-06-29 CA CA002530880A patent/CA2530880A1/en not_active Abandoned
- 2004-06-29 DK DK04738961.4T patent/DK1643985T3/da active
- 2004-06-29 AU AU2004253225A patent/AU2004253225A1/en not_active Abandoned
-
2005
- 2005-11-28 IS IS8154A patent/IS8154A/is unknown
-
2006
- 2006-01-03 IL IL172965A patent/IL172965A0/en unknown
- 2006-01-17 NO NO20060242A patent/NO20060242L/no not_active Application Discontinuation
-
2010
- 2010-04-21 US US12/764,348 patent/US20100267772A1/en not_active Abandoned
-
2012
- 2012-07-19 US US13/552,699 patent/US20130217776A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR047553A1 (es) | 2006-01-25 |
US20100267772A1 (en) | 2010-10-21 |
CA2530880A1 (en) | 2005-01-13 |
IS8154A (is) | 2005-11-28 |
DE602004031527D1 (de) | 2011-04-07 |
DK1643985T3 (da) | 2011-06-06 |
AU2004253225A1 (en) | 2005-01-13 |
EP1643985A1 (en) | 2006-04-12 |
EP1643985B1 (en) | 2011-02-23 |
US20130217776A1 (en) | 2013-08-22 |
WO2005002562A1 (en) | 2005-01-13 |
US20060205754A1 (en) | 2006-09-14 |
ATE499096T1 (de) | 2011-03-15 |
NO20060242L (no) | 2006-01-17 |
CN1852706A (zh) | 2006-10-25 |
JP2007513052A (ja) | 2007-05-24 |
IL172965A0 (en) | 2006-06-11 |
KR20060032598A (ko) | 2006-04-17 |
MXPA06000018A (es) | 2006-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0411665A (pt) | uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina | |
AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
BR9913288A (pt) | Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico | |
BR0013122A (pt) | Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina | |
ATE417607T1 (de) | Sphingolipide gegen krankhafte prozesse in lipid rafts | |
ATE399005T1 (de) | Pharmazeutische zusammensetzung aus einem beta-3- adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor und deren verwendung zur behandlung von blasenfunktionsstoerungen | |
BRPI0517481A (pt) | método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica | |
BR0008847A (pt) | Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas | |
EA200801551A1 (ru) | Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы | |
UY28041A1 (es) | Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial. | |
BR9911440A (pt) | Composição para a prevenção e/ou tratamento de osteoporose e alterações devido à sìndrome de menopausa | |
UY27993A1 (es) | Derivados de 4-pirrolidino-fenil-bencil eter | |
ECSP055885A (es) | Derivados de carbostirilo e inhibidores de la recaptacion de serotonina que sirven para el tratamiento de desordenes en el humor | |
BRPI0408902A (pt) | composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca | |
BR9912179A (pt) | Composição neuroprotetora para a prevenção e/ou tratamento de alterações nervosas e do comportamento devido a estados de ansiedade ou depressão | |
BRPI0411176A (pt) | combinação farmacêutica consistindo de modafinil e outra droga | |
BR9914419A (pt) | Terapia para melhoria da percepção | |
BR0317573A (pt) | Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos | |
BRPI0212298B8 (pt) | composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico | |
AR047719A1 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri | |
BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
BRPI0418973A (pt) | composições de risedronato e seus métodos de uso | |
BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
BR0312696A (pt) | Tratamento tópico de doenças da pele | |
AR054435A1 (es) | Agente para profilaxis o terapia contra la depresion o desorden de ansiedad |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |